Aardvark Therapeutics, Inc. Common Stock (AARD) vs Genelux Corporation (GNLX)

A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and Genelux Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AARD

Aardvark Therapeutics, Inc. Common Stock

$114M

$5.22HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

GNLX

Genelux Corporation

$117M

$2.60HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — AARD vs GNLX

growth of $100 · dividends reinvested · last 2y

AARD -63.5% (-39.6%/yr)GNLX -52.4% (-31.0%/yr)GNLX compounded faster over this window

AARD GNLX

AARD vs GNLX: by the numbers

•GNLX is the larger company ($117M vs $114M market cap).
•Both run net losses; AARD's is the smaller (0.00% vs -422412.50% net margin).

Metrics side by side

Valuation

Metric	AARD	GNLX
P/S ratio	N/A	14573.14
P/B ratio	1.53	7.24

Profitability

Metric	AARD	GNLX
Gross margin	0.00%	-7075.00%
Operating margin	0.00%	-415175.00%
Net margin	0.00%	-422412.50%
ROE	-93.44%	-209.73%
ROIC	-97.99%	-192.18%

Go deeper

Full AARD analysis Full GNLX analysis Interactive comparison tool

Dig into the metrics

Aardvark Therapeutics, Inc. Common Stock ROE Genelux ROE Aardvark Therapeutics, Inc. Common Stock operating margin Genelux operating margin Aardvark Therapeutics, Inc. Common Stock revenue growth Genelux revenue growth Aardvark Therapeutics, Inc. Common Stock free cash flow Genelux free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.